Author

Lisa M. Massoudi

Colorado State University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 5 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Approach:statistical model· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Gregory T. RobertsoniD· 5 shared Allison A. BaumaniD· 3 shared Firat KayaiD· 3 shared Matthew D. ZimmermaniD· 3 shared Nicholas D. WalteriD· 3 shared Reem Al MubarakiD· 3 shared Camille M. MooreiD· 2 shared Elizabeth A. WynniD· 2 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

Gregory T. RobertsonORCID

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

DDU384: A new preclinical candidate for the treatment of Tuberculosis

Simon R. Green, Kirsteen I. Buchanan, Helena I. Boshoff, Paul J. Koovits, Dinakaran Murugesan, Cristina De Cozar-Gallardo, Ana Yepes, Eik Hoffmann, Lisa M. Massoudi, Paul J. Converse, Oliver D. Komm, Laura Guijarro-López, Patricia Casado, Paul Scullion, Adolfo García-Pérez, , Laura A. T. Cleghorn

This paper identifies DDU384, a new compound with potent in vivo efficacy against tuberculosis in murine models, showing potential to improve current treatment options.

bioRxiv · Oct 27, 2026 · PreprintMicrobiology

Comprehensive preclinical reevaluation of PaBQU and DBQU regimens identifies lesional liability in hard-to-treat forms of tuberculosis

Nicholas D. Walter, Lisa M. Massoudi, Allison Bauman, Noalani D. Benedict, Nathan Peroutka‐Bigus, Michelle E. Ramey, Reem Al Mubarak, Samantha Pauly, Firat Kaya, Linda Chaba, Matthew D. Zimmerman, Debra Flood, David Hermann, Khisimusi Mdluli, David L. Holtzman, , Gregory T. Robertson

This study reevaluates PaBQU and DBQU regimens in mouse models, finding they have lesional liability in complex lesions, which may explain their failure in a human trial.

bioRxiv · Sep 17, 2026 · PreprintMicrobiology

Physiologic recovery of Mycobacterium tuberculosis from drug injury: A molecular study of post antibiotic effect in mice

Jo Hendrix, Reem Al Mubarak, Adeline Bateman, Lisa M. Massoudi, Karen Rossmassler, Firat Kaya, Matthew Zimmerman, Elizabeth A. Wynn, Martin I. Voskuil, Gregory T. Robertson, Camille M. Moore, Nicholas D. Walter

This study investigates the physiologic recovery of Mycobacterium tuberculosis in mice after antibiotic treatment, finding that recovery is slow, sequential, and incomplete, with longer treatment leading to slower recovery.

bioRxiv · Feb 25, 2025 · PreprintMicrobiology

Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice

Elizabeth A. Wynn, Christian Dide-Agossou, Reem Al Mubarak, Karen Rossmassler, Victoria A. Ektnitphong, Allison Bauman, Lisa M. Massoudi, Martin I. Voskuil, Gregory T. Robertson, Camille M. Moore, Nicholas D. Walter

This study examines how prolonged antibiotic treatment affects M. tuberculosis physiology in mice, finding that sterilizing and non-sterilizing antibiotics induce distinct transcriptional responses.

Antimicrobial Agents and Chemotherapy · Jan 17, 2025Peer-reviewedGenomics

Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis

Allison A. Bauman, Jansy Passiflora Sarathy, Firat Kaya, Lisa M. Massoudi, Michael S. Scherman, Courtney Hastings, Jiuyu Liu, Min Xie, Elizabeth J. Brooks, Michelle E. Ramey, Isabelle L. Jones, Noalani D. Benedict, Madelyn R. Maclaughlin, Jake A. Miller-Dawson, Samanthi L. Waidyarachchi, , Gregory T. Robertson

This study shows that MBX-4888A, a spectinamide, shortens tuberculosis treatment in murine models by improving tissue distribution and working well with rifampin and pyrazinamide.

Antimicrobial Agents and Chemotherapy · Sep 30, 2024Peer-reviewedMicrobiology